Enanta Pharmaceuticals (ENTA) Receivables Refunds: 2020-2025
Historic Receivables Refunds for Enanta Pharmaceuticals (ENTA) over the last 4 years, with Jun 2025 value amounting to $24,000.
- Enanta Pharmaceuticals' Receivables Refunds fell 99.93% to $24,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $24,000, marking a year-over-year decrease of 99.93%. This contributed to the annual value of $32.0 million for FY2024, which is 3.21% up from last year.
- As of Q2 2025, Enanta Pharmaceuticals' Receivables Refunds stood at $24,000, which was down 99.93% from $33.8 million recorded in Q1 2025.
- Enanta Pharmaceuticals' 5-year Receivables Refunds high stood at $37.3 million for Q3 2021, and its period low was $24,000 during Q2 2025.
- Moreover, its 3-year median value for Receivables Refunds was $31.9 million (2023), whereas its average is $28.0 million.
- In the last 5 years, Enanta Pharmaceuticals' Receivables Refunds surged by 185.68% in 2021 and then crashed by 99.93% in 2025.
- Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Receivables Refunds stood at $28.8 million in 2021, then decreased by 0.17% to $28.7 million in 2022, then rose by 10.56% to $31.7 million in 2023, then grew by 2.24% to $32.4 million in 2024, then slumped by 99.93% to $24,000 in 2025.
- Its last three reported values are $24,000 in Q2 2025, $33.8 million for Q1 2025, and $32.4 million during Q4 2024.